News
IMMP
2.920
-2.67%
-0.080
Weekly Report: what happened at IMMP last week (0429-0503)?
Weekly Report · 2d ago
Immutep’s Efti Shows Promise in Sarcoma Trial
TipRanks · 5d ago
BRIEF-Immutep's Efti Reports Positive Initial Clinical Data
Reuters · 6d ago
Initial Clinical Data Reported From Immutep's Efti Combined With Radiotherapy And Checkpoint Inhibitor From Phase II Trial In Soft Tissue Sarcoma
Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial Four of six patients treated have very good, near-complete pathologic responses that are rarely observed with standard therapies. Soft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical need.
Benzinga · 6d ago
Immutep: Realizing The Expected Catalysts, With More To Come
Immutep Limited is focused on developing novel treatments targeting LAG3, an immune checkpoint for various tumor types. The company's pipeline includes eftilagimod, which has shown promising response rates in thoracic malignancies. Immutep should have sufficient funding for 9–10 quarters of research.
Seeking Alpha · 6d ago
*Immutep Started With A$1.00/Share Target Price by Canaccord Genuity>IMM.AU
Dow Jones · 04/30 22:17
*Immutep Started at Buy by Canaccord Genuity >IMM.AU
Dow Jones · 04/30 22:17
Immutep Shares Upbeat Clinical Trials Update
TipRanks · 04/30 11:29
Weekly Report: what happened at IMMP last week (0422-0426)?
Weekly Report · 04/29 10:26
*Immutep Price Target Raised 23% to A$0.80/Share by Bell Potter
Dow Jones · 04/28 22:38
Immutep’s Efti Shows Promise in Cancer Therapy, Analyst Maintains Buy Rating
TipRanks · 04/26 05:58
Immutep Buy Rating Justified by Strong Clinical Trial Results and Promising Future Prospects
TipRanks · 04/25 16:55
Immutep’s Efti Shows Promise in Cancer Trial
TipRanks · 04/25 10:34
Immutep reports promising efti/Keytruda data for head and neck cancer
Immutep reports promising efti/Keytruda data for head and neck cancer. The drug candidate is being tested in combination with Merck’s blockbuster cancer drug Keytruda. The company expects to release data on the primary endpoint in the first half of 2024.
Seeking Alpha · 04/24 20:08
Immutep Reports Positive Preliminary Topline Results From TACTI-003 Cohort B
NASDAQ · 04/24 19:20
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 27.8% to $0.58 during Wednesday's regular session. The company's market cap stands at $4.4 million. Prenetics Global and Alterity Therapeutics also moved upwards.
Benzinga · 04/24 16:31
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Immutep Limited released preliminary topline results from a head and neck squamous cell carcinoma trial. The company is testing eftilagimod alpha in combination with Keytruda. The combination showed an overall response rate of 26.9% in 26 patients with negative PD-L1 expression.
Benzinga · 04/24 14:43
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector -0.08% to 1644.11. Pharmaceuticals, Biotechnology & Life Science contributes 58% to the index.
Seeking Alpha · 04/24 14:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. Syra Health stock rose 14.96% during the session. Sage Therapeutics and Evotec were among the losers in the day's trading.
Benzinga · 04/24 12:06
IMMUTEP ANNOUNCES POSITIVE PRELIMINARY TOPLINE RESULTS FROM TACTI-003 COHORT B
Reuters · 04/24 12:00
More
Webull provides a variety of real-time IMMP stock news. You can receive the latest news about Immutep through multiple platforms. This information may help you make smarter investment decisions.
About IMMP
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.